3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
7
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Adenocarcinoma Of Esophagus
3
Stomach Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Liver Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Uterine Cervical Neoplasms
1
Testicular Neoplasms
1
Sarcoma
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Mesothelioma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Kidney Neoplasms
1
Hematologic Neoplasms
1
Interventions
pembrolizumab
24
Radiotherapy
21
Cisplatin
21
Cetuximab
13
Carboplatin
11
Paclitaxel
8
Nivolumab
8
durvalumab
7
Radiotherapy, Intensity-Modulated
6
Docetaxel
6
Fluorouracil
5
Cyclophosphamide
5
zalutumumab
4
Everolimus
4
Amifostine
4
spartalizumab
3
fludarabine
3
epacadostat
3
cemiplimab
3
Ipilimumab
3
Immune Checkpoint Inhibitors
3
Gefitinib
3
Filgrastim
3
Erlotinib Hydrochloride
3
Celecoxib
3
Capecitabine
3
selpercatinib
2
palbociclib
2
fludarabine phosphate
2
bintrafusp alfa protein, human
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Head and Neck Neoplasms
×
tremelimumab
×
Clear all
NCT03518606
2025-01-15
MOVIE
UNICANCER
Phase 1/2
Completed
126 enrolled